ArticleBioactive materials2026
Bacterial synthesis of personalized biomimetic biological cornea.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal transplantation is one of the most effective treatments for corneal blindness. However, aside from clinical donor shortage, matching the transparency, curvature, and mechanical properties of artificial corneal materials with autologous corneas is challenging. This study employs bacterial synthetic biology, combining a curvature-customized model with an aldehyde modification system to develop a personalized biomimetic biological cornea (DBC@L-Cel) with a nanofiber network structure and customizable curvature and morphology. Dialdehyde bacterial nanocellulose (DBC) achieves a transmittance of 91.91 %, with optical and mechanical properties matching those of natural corneas. The incorporation of human-derived corneal lenticule microparticles (L) and Celastrol (Cel) significantly enhances the biocompatibility, adhesiveness, and anti-scarring capabilities of DBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.